### 1 Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2

# 2 infection is associated with disease severity and fatal outcome

- 3 Yang Yang<sup>†</sup>, Chenguang Shen<sup>†</sup>, Jinxiu Li<sup>†</sup>, Jing Yuan, Minghui Yang, Fuxiang Wang,
- 4 Guobao Li, Yanjie Li, Li Xing, Ling Peng, Jinli Wei, Mengli Cao, Haixia Zheng,
- 5 Weibo Wu, Rongrong Zou, Delin Li, Zhixiang Xu, Haiyan Wang, Mingxia Zhang,
- 6 Zheng Zhang, Lei Liu\*, Yingxia Liu\*
- 7

8 Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research
9 Center for infectious disease, State Key Discipline of Infectious Disease, Shenzhen
10 Third People's Hospital, Second Hospital Affiliated to Southern University of Science
11 and Technology, Shenzhen, China.

12

13 *†*These authors contributed equally.

14 \*email: yingxialiu@hotmail.com; liulei3322@aliyun.com

15

The outbreak of Coronavirus Disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, December 2019, and continuously poses a serious threat to public health. Our previous study has shown that cytokine storm occurred during SARS-CoV-2 infection, while the detailed role of cytokines in the disease severity and progression remained unclear due to the limited case number. In this study, we examined 48 cytokines in the plasma samples from 53 COVID-19 cases, among whom 34 were severe cases, and the others

23	moderate. Results showed that 14 cytokines were significantly elevated upon
24	admission in COVID-19 cases. Moreover, IP-10, MCP-3, and IL-1ra were
25	significantly higher in severe cases, and highly associated with the $PaO_2/FaO_2$ and
26	Murray score. Furthermore, the three cytokines were independent predictors for the
27	progression of COVID-19, and the combination of IP-10, MCP-3 and IL-1ra showed
28	the biggest area under the curve (AUC) of the receiver-operating characteristics (ROC)
29	calculations. Serial detection of IP-10, MCP-3 and IL-1ra in 14 severe cases showed
30	that the continuous high levels of these cytokines were associated with disease
31	deterioration and fatal outcome. In conclusion, we report biomarkers that closely
32	associated with disease severity and outcome of COVID-19. These findings add to
33	our understanding of the immunopathologic mechanisms of SARS-CoV-2 infection,
34	providing novel therapeutic targets and strategy.

35

36 Coronaviruses are the largest known viruses with a single positive- sense genome of about 31Kb which could infect a wide range of different species, and mainly infect 37 respiratory and intestinal tract causing a wide range of symptoms <sup>1</sup>. Six members of 38 coronaviruses that have been found to infect human beings, including HCoV-229E, 39 HCoVOC43, HCoV-NL63, and HCoV-HKU1, Severe Acute Respiratory Syndrome 40 coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus 41 (MERS-CoV)<sup>1,2</sup>. Until recently, human infection with the novel severe acute 42 respiratory syndrome coronavirus 2 (SARS-CoV-2) was firstly identified in late 43 December, 2019, in Wuhan, China<sup>3,4</sup>. As of Feb. 29, 2020, a total of 79824 44 Coronavirus Disease 2019 (COVID-19) cases with 2870 fatal cases were reported <sup>5</sup>. 45 Furthermore, another 53 countries have also reported COVID-19 cases, posing a 46 serious threat of public health <sup>6</sup>. Studies have revealed that penumonia is the most 47 48 common complications following SARS-CoV-2 infection, and followed by acute respiratory distress syndrome (ARDS)<sup>7,8</sup>. Inflammation is the body's first coordinated 49 line of defense against tissue damage caused by either injury or infection, involving 50 activating both the innate and adaptive immune responses <sup>9</sup>. However, exuberant 51 immune responses following infection have been described as a cytokine storm, 52 associated with excessive levels of proinflammatory cytokines and widespread tissue 53 damage including ARDS<sup>10</sup>. 54

55 Cytokine storm has been found during the infection of influenza viruses <sup>11-16</sup> as 56 well as coronavirues <sup>17-24</sup>, and contributes to acute lung injury and development of 57 ARDS <sup>2</sup>. Preliminary studies have shown that SARS-CoV-2 infection triggers 58 cytokine storm, and results in the increase of a variety of cytokine/chemokine <sup>25,26</sup>. 59 However, the detailed role of cytokines in diseases severity and progression remains 50 unknown. In this study, we recruited 53 COVID-19 cases with 34 severe cases and 19

61 moderate cases defined according to China National Health Commission Guidelines 62 for Diagnosis and Treatment of SARS-CoV-2 infection, and analyzed the plasma 63 cytokine/chemokine profile in detail. Most of the severe cases (73.5%) were  $\geq 60$ 64 years-old, while the moderate cases were mainly in the group of 16-59 years-old (63.2%) (Table S1). The initial symptoms, co-existing chronic medical conditions, 65 intervals of illness onset to admission and antiviral treatment were similar between 66 the two groups. Complications occurred more frequently in the severe cases, 67 68 including ARDS, respiratory failure, hepatic and renal insufficiency (Table S1). A 69 complete blood count with differential was assessed for each patient either on the date 70 of hospital admission, or at the earliest time-point and thereafter (Table 1). The 71 percentage of lymphocyte (LYM) and neutrophil (NEU) as well as the CD4 and CD8 72 counts were significantly lower in the severe cases, indicating a possible dysfunction 73 of immune responses.

Then the expression profile of cytokines/chemokines of COVID-19 cases upon 74 75 admission was analyzed. Elevated concentrations of both pro- and anti-inflammatory 76 cytokines were observed in these cases including IFN- $\gamma$  (interferon, IFN), IL-1ra (interleukin, IL), IL-2ra, IL-6, IL-10, IL-18, HGF (hepatocyte growth factor), MCP-3 77 78 (monocyte chemotactic protein-3), MIG (monokine induced gamma interferon), 79 M-CSF (macrophage colony stimulating factor), G-CSF (granulocyte 80 colony-stimulating factor), MIG-1a (macrophage inflammatory protein 1 alpha) 81 CTACK (cutaneous T-cell-attracting chemokine) and IP-10 (interferon gamma induced protein 10), when compared with healthy control, indicating that cytokine 82 storm occurred following SARS-CoV-2 infection (Figure 1) as previously reported <sup>3,25</sup>. 83 Similar phenomenon was also observed in SARS-CoV <sup>17-21</sup> and MERS-CoV <sup>22-24</sup> 84 85 infected patients, despite that the expression profiles were virus specific. Meanwhile,

we compared the plasma cytokine/chemokine levels collected from severe and 86 87 moderate cases at different days after illness onset (d.a.o). The results showed that 88 most of the cytokines were comparable between the two groups and maintained high 89 level even at the later stage of the disease ( $\geq 15$  d.a.o). However, IP-10, MCP-3, IL-1ra and MIG were significantly higher in samples from severe cases in all the three 90 groups of sample collection time, even though statistical significance was not 91 92 observed in IL-1ra and MIG. Notably, IP-10 in the severe cases possessed a high and 93 similar expression level at all groups of sample collection time. On the contrary, IP-10 94 in moderate cases was significantly lower and further decreased a lot at  $\geq 15$  d.a.o. 95 Moreover, comparison of these fourteen cytokines between the severe and moderate 96 cases showed significantly higher levels of IP-10, MCP-3 and IL-1ra in the severe cases (Figure 1). Spearman rank coefficient correlation analysis showed that IP-10, 97 98 MCP-3 and IL-1ra expression levels were highly correlated with  $PaO_2/FaO_2$  and 99 Murray scores. Interestingly, the viral load (displayed as Ct values) showed obvious 100 correlation with only IP-10, while not MCP-3 and IL-1ra, as well as the  $PaO_2/FaO_2$ and Murray scores (Figure S2). Our previous study has found that the viral shedding 101 102 in COVID-19 cases is complicated and the viral loads obtained from the regularly 103 used upper respiratory specimens might not consistent with the real case, especially for the severe cases <sup>27</sup>. Meanwhile, the main distribution of viruses in the severe and 104 105 moderate cases were also different, which might influence the induction of cytokines 106 as well. Indeed, studies have found that high viral loads in some types of viral infections correlated with severe diseases <sup>28-30</sup>, while not for all of them <sup>31</sup>. These 107 108 results suggested that the production of specific cytokines while not the viral burden 109 might play central in the pathogenesis COVID-19.

110 We further analyzed whether these cytokines could be used as predictors for the

111 disease severity and progression of COVID-19. Firstly, we calculated the receiver 112 operating characteristic (ROC) of each single cytokine using the expression levels 113 upon admission. Results showed that the area under the curve (AUC) of the ROC was 114 0.915, 0.765 and 0.792 for IP-10, MCP-3 and IL-1ra, respectively (Figure 3). Then we tested the different combination of these cytokines for the prediction of disease 115 progression. Combinations of the three cytokines showed the highest AUC of 0.943, 116 followed by the combination of IP-10 and MCP-3 (0.927) as well as the combination 117 118 of IP-10 and IL-1ra (0.923) (Figure 3). Furthermore, we analyzed the serial change of the three cytokines in 14 severe cases. In the two fatal cases (cases 1 and 2), the 119 120 expression levels were significantly high upon admission and maintained high levels 121 during the disease progression. Meanwhile, five cases (cases 7~9, 11 and 13) with 122 continuously high levels of these cytokines, especially IP-10 and MCP-3, were still in 123 critical condition. On the contrary, cases 3~6, 10, 12 and 14 with lower levels or 124 significantly decreased levels of these cytokines showed an obvious 125 improvement of the disease, and became moderate cases (cases 4, 10, 12 and 14) or discharged from hospital (cases 3, 5, 6 and 10). These results indicated that these 126 127 three cytokines could be considered as biomarkers to predict disease progression and 128 outcome of SARS-CoV-2 infections.

Cytokine storm with uncontrolled proinflammatory responses induce significant immunopathology and severe disease outcomes during some viral infections, indicating an important role in the pathogenesis of these viruses <sup>2,32</sup>. Accordingly, not only the pathogens but also the pathogen induced cytokine storm should be considered during the treatment. Therapy strategy with a combination of antimicrobial and immunotherapy may produce a more favorable outcome <sup>9</sup>. Corticosteroids which could downregulate proinflammatory cytokine transcription and subsequently inhibit

the cytokine storm  $^{33}$ , and the antiviral cytokine interferon- $\alpha$  were widely used during 136 the treatment of COVID-19<sup>8,34</sup>. However, use of high-dose corticosteroids has been 137 shown to be associated with an increase in mortality and significantly longer 138 durations of viral shedding in H7N9 infected patients <sup>35</sup>, which is of concern. The 139 140 results of our study suggested a crucial role of IP-10 in the pathogenesis of 141 SARS-CoV-2, which has also been shown to be associated with disease severity of H5N1, H1N1, SARS-CoV and MERS-CoV 16,24,29,36. A recent study has found that 142 143 IP-10 (CXCL10)-CXCR3 signaling appears to be a critical factor for the exacerbation of the pathology of ARDS <sup>37</sup>. Thus, modulators such as antibody targeting IP-10 144 145 might be a promising therapeutic strategy in the treatment of the acute phase of ARDS 146 to ameliorates acute lung injury as shown in H1N1 mouse model <sup>37,38</sup>.

In summary, we compared the differences of cytokines profiles between severe and moderate COVID-19 cases, and found that IP-10, MCP-3 and IL-1ra were significantly associated with disease severity and progression of COVID-19. Our results added to our understanding of the immunopathologic mechanisms of SARS-CoV-2 infection, and suggest a novel therapeutic strategy using modulators or antibodies against theses cytokines, especially IP-10.

# 153 **METHODS**

### 154 **Patient information and data collection**

155 Subjects presented in this study were hospitalized COVID-19 patients (N=53), among 156 whom 34 were defined as severe cases according to China National Health 157 Commission Guidelines for Diagnosis and Treatment of 2019-nCoV infection. Healthy controls (N=8) were also included. Clinical information and laboratory result 158 were collected at the earliest time-point after hospitalization. The study protocol was 159 160 approved by the Ethics Committees of Shenzhen Third People's Hospital 161 (SZTHEC2016001). Informed consents were obtained from all patients or patients 162 family members. The study was conducted in accordance with the International 163 Conference on Harmonisation Guidelines for Good Clinical Practice and the 164 Declaration of Helsinki and institutional ethics guidelines.

# 165 Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR)

qRT-PCR were done as previously reported <sup>26,34</sup>. In brief, throat swabs, nasal swabs, 166 167 sputum and BALF specimens were collected from laboratory-confirmed COVID-19 cases upon admission and thereafter. Viral RNAs were extracted from clinical 168 specimens using the QIAamp RNA Viral Kit (Qiagen, Heiden, Germany). A China 169 Food and Drug Administration (CDFA) approved commercially kit (GeneoDX Co., 170 171 Shanghai, China) were used for the detection of SARS-CoV-2 specific RNAs. 172 Samples with a cycle threshold (Ct) value  $\leq 37.0$  were considered putatively positive. 173 Samples whose Ct was higher than 37 were re-tested and considered positive if Ct 174 was  $\geq$  37 but  $\leq$  40 and negative if viral RNAs were undetectable on the second test.

# 175 Disease severity classification

176 Disease severity classification and Murray Score calculation were evaluated as previously reported <sup>26</sup>. Severity of 2019-nCoV infection was graded according to 177 China National Health Commission Guidelines for Diagnosis and Treatment of 178 179 SARS-CoV-2 infection. Laboratory confirmed patients with fever, respiratory manifestations and radiological findings indicative of pneumonia were considered 180 181 moderate cases (COVID-19-M). Laboratory confirmed patients who met any of the 182 following were considered to have severe COVID-19 (COVID-19-S): 1) respiratory 183 distraction (respiration rate $\geq$ 30/min; 2) resting oxygen saturation $\leq$ 93%, or 3) arterial oxygen partial pressure (PaO<sub>2</sub>) / fraction of inspired oxygen (FiO<sub>2</sub>)  $\leq$  300 mmHg (1 184 185 mmHg = 0.133 kPa). Laboratory confirmed patients who had any of the following 186 were considered in critical condition: 1) respiratory failure requiring mechanical ventilation, 2) shock, or 3) failure of other organs requiring intensive care unit (ICU). 187

# 188 Quantification of hypoxia and Murray Score

The partial pressure of oxygen (PaO<sub>2</sub>) in arterial blood taken from the patients at various time-points after hospitalization is measured by the ABL90 blood gas analyzer (Radiometer). The fraction of inspired oxygen (FiO2) is calculated by the following formula:  $FiO_2 = (21 + oxygen flow (in units of l/min) \times 4) /100$ . The

PaO<sub>2</sub>/FiO<sub>2</sub> ratio (in units of mmHg) is calculated by dividing the PaO<sub>2</sub> value with the FiO<sub>2</sub> value. A PaO<sub>2</sub>/FiO<sub>2</sub> ratio less than or equal to 100 mmHg is considered one of the criteria for severe acute respiratory distress syndrome (ARDS). Murray Score were calculated as reported <sup>39</sup>.

# 197 Cytokine and chemokine measurements

198 The plasma of patients with laboratory-confirmed COVID-19 cases (N=53) were

collected at the earliest possible time-point after hospitalization and thereafter. The plasma of healthy subjects (N=8) were included as the negative control group. The concentrations of 48 cytokines and chemokines were measured using Bio-Plex Pro Human Cytokine Screening Panel (Bio-Rad) as previously reported  $^{15,26}$ .

# 203 Statistical analysis

204 Fisher exact test was used to compare the indicated rates between the moderate and 205 severe cases. Mann-Whitney U test was used to compare plasma cytokine levels 206 between two groups. The Spearman rank correlation coefficient was used for linear 207 correlation analysis between the expression level of plasma cytokine and PaO2/FiO2 208 ratio, Murray score as well as viral loads of COVID-19 cases. The area under the 209 receiver operating characteristic (ROC) curve (AUC) of plasma cytokine levels was 210 estimated for the moderate and severe cases. All statistical tests were calculated using 211 SPSS 20.0 for Windows (IBM, Chicago, USA). P value less than 0.05 was considered 212 statistically significant.

# 213 **References**

214 215 216	1	Su, S. <i>et al.</i> Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. <i>Trends Microbiol</i> <b>24</b> , 490-502, doi:10.1016/j.tim.2016.03.003 (2016).
217 218 219	2	Channappanavar, R. & Perlman, S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. <i>Semin Immunopathol</i> <b>39</b> , 529-539, doi:10.1007/s00281-017-0629-x (2017).
220 221	3	Zhu, N. <i>et al.</i> A Novel Coronavirus from Patients with Pneumonia in China, 2019. <i>N Engl J Med</i> , doi:10.1056/NEJMoa2001017 (2020).
222 223 224	4	Wenjie, T. <i>et al.</i> A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019–2020. <i>China CDC Weekly</i> <b>2</b> , 61-62 (2020).
225 226	5	China, N. H. C. o. t. P. s. R. o. <i>Daily briefing on novel coronavirus cases in China</i> , < <u>http://en.nhc.gov.cn/2020-02/05/c_76219.htm</u> > (2020).
227 228 229	6	WHO.NovelCoronavirus(COVID-19)situation,< <a href="https://experience.arcgis.com/experience/685d0ace521648f8a5beeee1b9125">https://experience.arcgis.com/experience/685d0ace521648f8a5beeee1b9125cd&gt; (2020).</a>
230 231 232	7	Wang, D. <i>et al.</i> Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. <i>Jama</i> , doi:10.1001/jama.2020.1585 (2020).
233 234	8	Guan, W. J. <i>et al.</i> Clinical Characteristics of Coronavirus Disease 2019 in China. <i>N Engl J Med</i> , doi:10.1056/NEJMoa2002032 (2020).
235 236 237	9	D'Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A. & Clark, G. C. Targeting the "cytokine storm" for therapeutic benefit. <i>Clin Vaccine Immunol</i> <b>20</b> , 319-327, doi:10.1128/cvi.00636-12 (2013).
238 239	10	Ben Salem, C. Acute Respiratory Distress Syndrome. <i>N Engl J Med</i> <b>377</b> , 1904, doi:10.1056/NEJMc1711824 (2017).
240 241 242 243	11	Zeng, H. <i>et al.</i> A(H7N9) virus results in early induction of proinflammatory cytokine responses in both human lung epithelial and endothelial cells and shows increased human adaptation compared with avian H5N1 virus. <i>J Virol</i> <b>89</b> , 4655-4667, doi:10.1128/jvi.03095-14 (2015).

244 245 246	12	Guo, J. <i>et al.</i> The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes. <i>Sci Rep</i> <b>5</b> , 10942, doi:10.1038/srep10942 (2015).
247 248	13	Zhou, J. <i>et al.</i> Biological features of novel avian influenza A (H7N9) virus. <i>Nature</i> <b>499</b> , 500-503, doi:10.1038/nature12379 (2013).
249 250 251 252	14	Yang, Y. <i>et al.</i> Comparison between human infections caused by highly and low pathogenic H7N9 avian influenza viruses in Wave Five: Clinical and virological findings. <i>J Infect</i> <b>78</b> , 241-248, doi:10.1016/j.jinf.2019.01.005 (2019).
253 254 255	15	Bi, Y. <i>et al.</i> Clinical and immunological characteristics of human infections with H5N6 avian influenza virus. <i>Clin Infect Dis</i> , doi:10.1093/cid/ciy681 (2018).
256 257 258	16	Wang, S. <i>et al.</i> Influenza virus-cytokine-protease cycle in the pathogenesis of vascular hyperpermeability in severe influenza. <i>J Infect Dis</i> <b>202</b> , 991-1001, doi:10.1086/656044 (2010).
259 260 261	17	Jiang, Y. <i>et al.</i> Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. <i>Am J Respir Crit Care Med</i> <b>171</b> , 850-857, doi:10.1164/rccm.200407-857OC (2005).
262 263	18	Huang, K. J. <i>et al.</i> An interferon-gamma-related cytokine storm in SARS patients. <i>J Med Virol</i> <b>75</b> , 185-194, doi:10.1002/jmv.20255 (2005).
264 265 266	19	Zhang, Y. <i>et al.</i> Analysis of serum cytokines in patients with severe acute respiratory syndrome. <i>Infect Immun</i> <b>72</b> , 4410-4415, doi:10.1128/iai.72.8.4410-4415.2004 (2004).
267 268 269	20	Wong, C. K. <i>et al.</i> Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. <i>Clin Exp Immunol</i> <b>136</b> , 95-103, doi:10.1111/j.1365-2249.2004.02415.x (2004).
270 271	21	Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. <i>Chin Med J (Engl)</i> <b>116</b> , 1283-1287 (2003).
272 273 274 275	22	Mubarak, A., Alturaiki, W. & Hemida, M. G. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development. <i>J Immunol Res</i> <b>2019</b> , 6491738, doi:10.1155/2019/6491738 (2019).

276	23	Mahallawi, W. H., Khabour, O. F., Zhang, Q., Makhdoum, H. M. & Suliman,							
277		B. A. MERS-CoV infection in humans is associated with a pro-inflammatory							
278		Th1	and	Th17	cytokine	profile.	Cytokine	104,	8-13,
279		doi:10	.1016/j.o	cyto.2018	.01.025 (2018	3).			

- 280 24 Faure, E. et al. Distinct immune response in two MERS-CoV-infected patients: bedside? from bench to PLoS 9. e88716, 281 can we go One doi:10.1371/journal.pone.0088716 (2014). 282
- 283 25 Huang, C. *et al.* Clinical features of patients infected with 2019 novel
  284 coronavirus in Wuhan, China. *Lancet* 395, 497-506,
  285 doi:10.1016/s0140-6736(20)30183-5 (2020).
- 286 26 Liu;, Y. *et al.* 2019-novel coronavirus (2019-nCoV) infections trigger an
  287 exaggerated cytokine response aggravating lung injury. *ChinaXiv* (2020).
- 288 27 Yang, Y. *et al.* Laboratory diagnosis and monitoring the viral shedding of
  289 2019-nCoV infections. *medRxiv* (2020).
- 28 Ng, K. T. *et al.* Viral Load and Sequence Analysis Reveal the Symptom
  291 Severity, Diversity, and Transmission Clusters of Rhinovirus Infections. *Clin*292 *Infect Dis* 67, 261-268, doi:10.1093/cid/ciy063 (2018).
- 293 29 de Jong, M. D. *et al.* Fatal outcome of human influenza A (H5N1) is
  294 associated with high viral load and hypercytokinemia. *Nat Med* 12, 1203-1207,
  295 doi:10.1038/nm1477 (2006).
- 296 30 de La Vega, M. A. *et al.* Ebola viral load at diagnosis associates with patient
  297 outcome and outbreak evolution. *J Clin Invest* 125, 4421-4428,
  298 doi:10.1172/jci83162 (2015).
- Garcia-Maurino, C. *et al.* Viral Load Dynamics and Clinical Disease Severity
  in Infants With Respiratory Syncytial Virus Infection. *J Infect Dis* 219, 1207-1215, doi:10.1093/infdis/jiy655 (2019).
- 302 32 Guo, X. J. & Thomas, P. G. New fronts emerge in the influenza cytokine storm.
   303 Semin Immunopathol 39, 541-550, doi:10.1007/s00281-017-0636-y (2017).
- 304 33 Rhen, T. & Cidlowski, J. A. Antiinflammatory action of glucocorticoids--new
  305 mechanisms for old drugs. N Engl J Med 353, 1711-1723,
  306 doi:10.1056/NEJMra050541 (2005).
- 307 34 Liu, Y. et al. Clinical and biochemical indexes from 2019-nCoV infected

308 309		patients linked to viral loads and lung injury. <i>Sci China Life Sci</i> , doi:10.1007/s11427-020-1643-8 (2020).			
310 311 312	35	Cao, B. <i>et al.</i> Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia. <i>Crit Care Med</i> 44, e318-328, doi:10.1097/ccm.00000000001616 (2016).			
313 314	36	Peiris, J. S. <i>et al.</i> Re-emergence of fatal human influenza A subtype H5N1 disease. <i>Lancet</i> <b>363</b> , 617-619, doi:10.1016/s0140-6736(04)15595-5 (2004).			
315 316 317	37	Ichikawa, A. <i>et al.</i> CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. <i>Am J Respir Crit Care Med</i> <b>187</b> , 65-77, doi:10.1164/rccm.201203-0508OC (2013).			
318 319 320	38	Wang, W. <i>et al.</i> Monoclonal antibody against CXCL-10/IP-10 ameliorates influenza A (H1N1) virus induced acute lung injury. <i>Cell Res</i> <b>23</b> , 577-580, doi:10.1038/cr.2013.25 (2013).			
321 322 323	39	Murray, J. F., Matthay, M. A., Luce, J. M. & Flick, M. R. An expanded definition of the adult respiratory distress syndrome. <i>Am Rev Respir Dis</i> <b>138</b> , 720-723, doi:10.1164/ajrccm/138.3.720 (1988).			

324

# 325 Acknowledgement

This work was supported by the National Natural Science Foundation of China (Grant 81802004) and the National Science and Technology Major Project (Grants 2018ZX10711001, 2017ZX10204401 and 2017ZX10103011), Shenzhen Science and Technology Research and Development Project (Grants JCYJ20180228162201541, 202002073000001) Sanming Project of Medicine in Shenzhen (SZSM201412003, SZSM201512005).

# 332 Author contributions

Y. Liu, L. Liu, Z. Zhang and Y. Yang conceived and guided the project. Y. Yang, C.
Shen, M. Yang carried out the experiments and analyzed the data. J. Li, J. Yuan, F.

- 335 Wang, Z. Wang, M. Cao, W. Wu, R. Zou, Y. Li, L. Xing, L. Peng, J. Wei, H. Zheng, Z.
- 336 Xu, and H. Wang collected clinical samples and the data. Y. Yang wrote the
- 337 manuscript. All the authors have read and approved the manuscript.

# 338 **Competing interests**

339 The authors declare no competing interests.

### 340 Figure legends

341 Figure 1. Comparison of serum cytokine/chemokine concentrations between 342 healthy volunteers and COVID-19 cases. Samples from severe (N=34) and 343 moderate (N=19) COVID-19 cases were collected at the earliest possible time-point after hospitalization for assays measuring the concentrations of 48 cytokines and 344 345 chemokines, and healthy subjects (N=8) were involved as control. Values were 346 graphed on a logarithmic scale and presented in units of pg/mL. P values between 347 0.01-0.05, 0.001-0.01 and 0.0001-0.001 were considered statistically significant (\*), very significant (\*\*) and extremely significant (\*\*\*), respectively, whereas ns 348 349 represents not significant.

350

#### 351 Figure 2. IP-10, MCP-3 and IL-1ra expression levels were highly correlated with

**PaO<sub>2</sub>/FiO<sub>2</sub> and Murray Score.** The expression levels of IP-10, MCP-3 and IL-1ra measured from plasma samples collected upon admission and thereafter and the corresponding PaO2/FiO2 and Murray Score at the same day were analyzed using spearman rank correlation analysis. The *r values* and *p values* were shown.

356

# Figure 3. The ROC curve of plasma cytokine levels for patients with mild and severe SARS-CoV-2-infections. The receiver operating characteristic (ROC) curve was calculated using SPSS. The area under the curve (AUC) of ROC for IP-10, MCP-3 and IL-1ra wad estimated using the expression levels upon admission. The P values of all AUC for the three cytokines were less than 0.05.

362

Figure 4. Dynamic changes of IP-10, MCP-10 and IL-1ra in 14 severe cases of COVID-19 with different outcome and progression. The expression levels measured at the indicated time-points of 14 severe cases were shown. The fatal cases were marked in red. Cases in critical condition were marked in blue, and the others were cases with moderate disease or discharged at present.

368

Figure S1. Comparison of the significantly elevated cytokines measured at different days post illness onset between severe and moderate COVID-19 cases. The expression levels of 14 significantly elevated cytokines measured at different days post illness onset were shown and compared between the severe and moderate COVID-19 cases. *P values* between 0.01-0.05, 0.001-0.01 and 0.0001-0.001 were considered statistically significant (\*), very significant (\*\*) and extremely significant (\*\*\*), respectively, whereas ns represents not significant.

376

Figure S2. Correlations between viral load and the cytokines of IP-10, MCP-3 and IL-1ra, as well as PaO2/FiO2 and Murray Score. The correlations between viral load and the cytokines of IP-10, MCP-3 and IL-1ra, as well as PaO2/FiO2 and Murray Score were analyzed using spearman rank correlation analysis. The *r values* and *p values* were shown. The viral loads were indicated as Ct values, and lower Ct values represented high viral load.




Figure 1




Figure 2




Figure 3




Figure 4




Figure S1




Figure S2

Variables†	Total (N=53)	Severe (N=34)	Moderate (N=19)	P values
WBC (× 10 <sup>9</sup> /L)	4.52 (3.43-5.89)	4.745 (3.54-5.91)	4.02 (3.42-5.55)	0.5623
LYM (%)	21.6 (15.1-32.1)	20.65(13.13-25.33)	29.40 (19.45-35.05)	0.0288
LYM (× 10 <sup>9</sup> /L)	1.12 (0.89-1.48)	1.13 (0.92-1.44)	1.12 (0.89-1.51)	0.7873
NEU (%)	67.4 (57.0-77.4)	69.95 (61.35-79.93)	60.90 (52.95-69.30)	0.0358
NEU (× 10 <sup>9</sup> /L)	2.8 (1.81-3.77)	2.98 (2.12-3.7)	2.32 (1.75-4.28)	0.5832
PLT (× 10 <sup>9</sup> /L)	171 (138-199)	173(141.5-192)	151 (133-204)	0.6172
AST (U/L)	33 (24-43)	32(22.5.41.5)	33 (24.5-45)	0.8358
ALT (U/L)	26 (16-30)	24.5 (18-29.25)	26 (15-33)	0.5656
TB (umol/L )	9.5 (7.8-12.1)	9.4 (8.10-11.6)	10.3 (6.85-15.35)	0.2973
CRE (µmol/L)	72.7 (54-82)	71.85 (54-80.75)	76 (59-96.5)	0.7739
BUN (mmol/L)	6.68 (3.65-5.59)	5.05 (3.71-5.84)	4.32 (3.57-5.17)	0.0829
CK (U/L)	100 (55.5-126)	83.5(56-126)	100 (55.75-122.5)	0.8519
CK-MB (ng/mL)	0.76 (0.28-1.21)	0.73 (0.28-1.02)	0.89 (0.375-1.775)	0.9289
LDH (U/L)	411.5 (205-530.75)	337(184-525)	432 (223-532)	0.5117
CRP (mg/L)	14.05 (5.7-29.96)	13.33 (5.1-28.28)	15.2 (11.37-32.46)	0.2033
PCT (ng/mL)	0.05 (0.031-0.077)	0.54(0.04-0.08)	0.041 (0.030-0.090)	0.5672
CD4 (count/µl)	362 (217.5-547.25)	329 (200.25-438.5)	559.5(377-784)	0.0027
CD8 (count/µl)	159 (122.5-335)	139 (97-183)	453.5 (232.8-586)	0.0167
CD4/CD8	2.05 (1.3-2.48)	2.26(1.35-2.82)	1.71 (1.21-2.17)	0.1391

Table 1. Laboratory results of COVID-19 patients in this study.

<sup>†</sup> Values shown represent the mean and inter-quartile range (IQR).

# Table S1. Epidemiological and clinical features of COVID-19 patients in this study.

	(N=53)	(N=34)	(N=19)	
Median age (range)	62 (51-65)	63.5(42-74)	51 (22-78)	0.0012
Age subgroups				
0-15 years	0/53 (0%)	0/26(0%)	0/27 (0%)	1
16-59 years	21/53 (39.6%)	9/34(26.5%)	12/19 (63.2%)	0.0179
≥60 years	32/53 (60.4%)	25/34(73.5%)	7/19 (36.8%)	0.0179
Male (%)	31/53 (58.5%)	22/34(64.7%)	9/19 (47.3%)	0.2557
Initial symptoms			× ,	
Fever	44/53 (83.0%)	31/34 (91.2%)	13/19 (68.4%)	0.0555
Cough	36/53 (67.9%)	24/34 (70.6%)	12/19 (63.2%)	0.7597
Headache	6/53 (11.3%)	5/34 (14.7%)	1/19(5.3%)	0.4020
Myalgia	28/53 (52.8%)	22/34 (57.7%)	6/19 (48.1%)	0.0254
Chill	6/53 (11.3%)	6/34 (17.6%)	0/19 (0%)	0.0770
Nausea or vomiting	0/53 (0%)	0/34 (0%)	0/19 (0%)	1
Diarrhea	4/53 (7.5%)	4/34 (11.8%)	0/19(0%)	0.2841
Co-existing chronic medical	+/JJ (1.J70)	+/3+(11.070)	0/17(070)	0.2041
conditions				
Chronic heart disease	19/31 (82.6%)	16/24 (65.0%)	3/7 (50%)	0.3839
Chronic lung disease	2/31 (8.7%)	1/24 (4.6%)	1/7 (14.3%)	0.4065
Chronic renal disease	2/31 (6.5%)	2/24 (8.3%)	0/7 (0%)	0.5402
Chronic liver disease	2/31 (8.7%)	1/24 (4.6%)	1/7 (14.3%)	1
Diabetes	6/31 (19.4%)	4/24 (16.7%)	2/7 (28.6%)	0.5959
Cancer	4/31 (12.9%)	2/24 (8.3%)	1/7 (14.3%)	0.5497
Bacterial co-infections	11/53 ( 20.8% )	8/34(23.5%)	3/19(15.8%)	0.7264
Interval, median days (IQR) <sup>+</sup>				
Onset to admission	4 (2, 6)	4 (3, 7)	2 (2, 5)	0.2287
Onset to starting antiviral treatment	4 (3, 7)	4 (4, 7)	4 (2.5, 6.5)	0.9184
Complications				
Pneumonia	53/53 (100%)	34/34 (100%)	19/19 (100%)	1
ARDS	37/53 (71.6%)	33/34 (97.1%)	0/19 (0%)	< 0.0001
Hepatic insufficiency	14/53 (26.4%)	13/34 (38.2%)	1/19 (5.3%)	0.0099
Renal insufficiency	10/53 (18.9%)	10/34 (29.4%)	0/19 (0%)	0.0091
Cardiac failure	3/53 (5.7%)	3/34 (8.8%)	0/27 (0%)	0.5450
Shock	2/53 (3.8%)	2/34 (5.8%)	0/27 (0%)	0.5312
Treatment				
Received antivirals $\leq 2$ days after	9/53 (16.9%)	4/34(11.8%)	5/19(26.3%)	0.2550
illness onset	),55 (10.970 J		2, 12 (20.270)	5.2550
Received antivirals 3-5 days after	23/53 (43.4%)	14/34(41.2%)	9/19(47.3%)	0.7750
illness onset			× ···· /	
Received antivirals $\geq 6$ days after	21/53 ( 39.6% )	14/34(42.2%)	7/19(36.8%)	0.7794
illness onset		. ,	· /	

Corticosteroid	16/53 ( 30.2% )	13/34(38.2%)	3/19(15.8%)	0.1226
Mechanical ventilation	25/53 (47.2%)	23/34 (67.7%)	0/19 (0%)	< 0.0001
Invasive mechanical ventilation	9/53 (17.0%)	9/34 (26.5%)	0/19 (0%)	0.0188